Skip to main content

Market Overview

Morgan Stanley Upgrades Medtronic On Exposure To COVID-19 Recovery

Share:
Morgan Stanley Upgrades Medtronic On Exposure To COVID-19 Recovery

Medtronic PLC (NYSE: MDT) is well-positioned for a COVID-19 recovery and has upside to the consensus estimates for fiscal 2022, according to Morgan Stanley.

The Medtronic Analyst: David Lewis upgraded Medtronic from Equal-Weight to Overweight and raised the price target from $120 to $140.

The Medtronic Thesis: Lagging implantable devices are expected to outperform, with risks being abated by vaccines, better hospital protocols, the availability of personal protective equipment and COVID-19 testing, Lewis said in the upgrade note.

“We see a winning formula for Medtronic, with the company well aligned to our pro-recovery thesis and a material disconnect between Street numbers and the improving post-COVID trajectory,” the analyst said. 

"Net, we model 10% FY22/FY19 revenue growth, and Gross and Operating Margins flat in FY22 relative to FY19, which look conservative in light of CFO Karen Parkhill's guidance for a return to normalized underlying growth and Operating Margins in F4Q21."

Morgan Stanley sees reason to be more bullish about Medtronic's pipeline and the turnaround required "to make the company a structural outperformer," Lewis said. 

MDT Price Action: Shares of Medtronic were up 2.39% at $114.75 at last check Tuesday. 

Photo courtesy of Medtronic. 

Latest Ratings for MDT

DateFirmActionFromTo
Feb 2021StifelMaintainsBuy
Feb 2021Credit SuisseMaintainsOutperform
Feb 2021SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!

Posted-In: David Lewis Morgan StanleyAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
BAMorgan StanleyMaintains250.0
BACMorgan StanleyMaintains38.0
AMCXMorgan StanleyMaintains55.0
AMBAMorgan StanleyMaintains125.0
ABNBMorgan StanleyMaintains160.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com